Charles River Abandons WuXi PharmaTech Just Days Before Crucial Shareholder Votes On Planned Merger
This article was originally published in PharmAsia News
Executive Summary
BEIJING - Like a prospective bride who has been jilted at the very last moment by a suitor, Shanghai's WuXi PharmaTech has been abandoned by the Massachusetts-headquartered Charles River Laboratories on the eve of the two contract research organizations' merger